| Literature DB >> 32272739 |
Carla Ferreri1, Anna Sansone1, Sandra Buratta2, Lorena Urbanelli2, Eva Costanzi2, Carla Emiliani2, Chryssostomos Chatgilialoglu1.
Abstract
A new pathway leading to the n-10 fatty acid series has been recently evidenced, starting from sapienic acid, a monounsaturated fatty acid (MUFA) resulting from the transformation of palmitic acid by delta-6 desaturase. Sapienic acid has attracted attention as a novel marker of cancer cell plasticity. Here, we analyzed fatty acids, including the n-10 fatty acid contents, and for the first time, compared cell membranes and the corresponding extracellular vesicles (EV) of two human prostatic adenocarcinoma cell lines of different aggressiveness (PC3 and LNCaP). The n-10 components were 9-13% of the total fatty acids in both cancer cell lines and EVs, with total MUFA levels significantly higher in EVs of the most aggressive cell type (PC3). High sapienic/palmitoleic ratios indicated the preference for delta-6 versus delta-9 desaturase enzymatic activity in these cell lines. The expressions analysis of enzymes involved in desaturation and elongation by qRT-PCR showed a higher desaturase activity in PC3 and a higher elongase activity toward polyunsaturated fatty acids than toward saturated fatty acids, compared to LNCaP cells. Our results improve the present knowledge in cancer fatty acid metabolism and lipid phenotypes, highlighting EV lipidomics to monitor positional fatty acid isomer profiles and MUFA levels in cancer.Entities:
Keywords: desaturase enzyme; elongase enzyme; extracellular vesicle lipidome; lipidomics; positional fatty acid isomer; sapienic acid; sebaleic acid; trans geometrical isomer
Year: 2020 PMID: 32272739 PMCID: PMC7226157 DOI: 10.3390/cancers12040900
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1Main structures of the C16 monounsaturated fatty acids (MUFA) family and their biosynthetic pathways, starting from palmitic acid.
Fatty acid methyl esters (FAME) (% relative quantities, %rel. quant.) obtained from membrane phospholipids of two different prostate cancer cell lines.
| FAME 1 | PC3 ( | LNCaP ( |
|---|---|---|
| C14:0 | 3.26 ± 0.32 | 3.44 ± 0.17 |
| C16:0 | 33.20 ± 1.33 | 33.60 ± 0.49 |
| 6 | 0.36 ± 0.04 | 0.56 ± 0.03 |
| 6 | 7.41 ± 0.35 | 7.81 ± 0.33 |
| 9 | 2.36 ± 0.17 | 1.96 ± 0.05 |
| C18:0 | 10.92 ± 0.54 | 11.48 ± 0.25 |
| 9 | 0.09 ± 0.01 | 0.11 ± 0.02 |
| 8 | 5.98 ± 0.75 | 4.55 ± 0.12 |
| 9 | 19.47 ± 0.72 | 18.62 ± 0.24 |
| 11 | 3.92 ± 0.30 | 3.90 ± 0.08 |
| 5 | 0.47 ± 0.03 | 0.52 ± 0.04 |
| mono- | 0.27 ± 0.05 | 0.24 ± 0.02 |
| C18:2 n-6 | 2.48 ± 0.19 | 1.97 ± 0.08 |
| C20:3 n-6 | 1.62 ± 0.16 | 1.73 ± 0.18 |
| C20:4 n-6 | 2.86 ± 0.23 | 4.01 ± 0.14 |
| mono- | 0.10 ± 0.01 | 0.11 ± 0.05 |
| C20:5 n-3 | 0.47 ± 0.06 | 0.37 ± 0.07 |
| C22:5 n-3 | 1.77 ± 0.19 | 1.53 ± 0.14 |
| C22:6 n-3 | 2.98 ± 0.18 | 3.49 ± 0.20 |
| SFA | 47.38 ± 1.39 | 48.52 ± 0.46 |
| MUFA | 39.14 ± 1.13 | 36.84 ± 0.59 |
| PUFA | 12.65 ± 0.37 | 13.62 ± 0.42 |
| n-6 | 6.96 ± 0.34 | 7.70 ± 0.31 |
| n-3 | 5.22 ± 0.15 | 5.40 ± 0.38 |
| n-6/n-3 | 1.34 ± 0.07 | 1.52 ± 0.19 |
| n-10 | 13.86 ± 0.97 | 12.89 ± 0.42 |
| Total | 0.83 ± 0.07 | 1.02 ± 0.06 |
1 FAME = fatty acid methyl ester. Identified by standard references and quantified as described in the Materials and Methods Section. Values are obtained in µg/mL considering the gas chromatography (GC) peak areas recognized and calibrated with standard references (corresponding to >98% of the total peaks of the chromatogram). 2 PC3, prostate cancer and LNCaP, Prostate; Derived From Metastatic Site: Left Supraclavicular Lymph Node. Values are expressed in percentages relative to the sum of all the quantities of the recognized peaks ± standard error of the mean (S.E.M) from the analyses of n = 8 cell samples of each type; statistical significance is estimated: * p-value ≤ 0.045; ** p-value ≤ 0.001; *** p-value ≤ 0.0009. Details of the statistical analysis are reported in the Materials and Methods Section.
Fatty acid methyl esters (FAME) (%rel. quant.) obtained from extracellular vesicles (EV) derived from two different prostate cancer cell lines.
| FAME 1 | PC3-EVs ( | LNCaP-EVs ( |
|---|---|---|
| C14:0 | 4.38 ± 1.17 | 5.27 ± 0.25 |
| C16:0 | 33.32 ± 0.74 | 35.62 ± 0.96 |
| 6 | 0.10 ± 0.02 | 0.48 ± 0.03 |
| 6 | 6.10 ± 1.59 | 8.13 ± 0.28 |
| 9 | 1.10 ± 0.26 | 1.59 ± 0.08 |
| C18:0 | 12.35 ± 0.52 | 15.34 ± 0.66 |
| 9 | 0.18 ± 0.04 | 0.22 ± 0.04 |
| 8 | 2.85 ± 0.67 | 4.32 ± 0.27 |
| 9 | 30.83 ± 4.41 | 15.43 ± 0.66 |
| 11 | 1.21 ± 0.08 | 1.57 ± 0.24 |
| 5 | 0.25 ± 0.03 | 0.62 ±0.07 |
| mono-trans C18:2 n-6 | 0.15 ± 0.03 | 0.20 ± 0.06 |
| C18:2 n-6 | 3.43 ± 0.50 | 2.91 ± 0.18 |
| C20:3 n-6 | 0.49 ± 0.08 | 0.98 ± 0.16 |
| C20:4 n-6 | 0.70 ± 0.15 | 2.05 ± 0.13 |
| mono-trans C20:4 | 0.05 ± 0.02 | 0.08 ± 0.02 |
| C20:5 n-3 | 0.29 ± 0.05 | 0.55 ± 0.09 |
| C22:5 n-3 | 0.54 ± 0.14 | 1.41 ± 0.19 |
| C22:6 n-3 | 1.68 ± 0.24 | 3.22 ± 0.23 |
| SFA | 50.05 ± 1.50 | 56.23 ± 0.61 |
| MUFA | 42.08 ± 2.25 | 31.05 ± 0.49 |
| PUFA | 7.39 ± 0.94 | 11.74 ± 0.41 |
| n-6 | 4.62 ± 0.57 | 5.94 ± 0.22 |
| n-3 | 2.51 ± 0.38 | 5.18 ± 0.32 |
| n-6/n-3 | 1.97 ± 0.17 | 1.18 ± 0.08 |
| n-10 | 9.20 ± 2.23 | 13.07 ± 0.50 |
| Total | 0.48 ± 0.08 | 0.98 ± 0.09 |
1 Identified by standard references and quantified as described in the Materials and Methods Section. Values are obtained in µg/mL considering the GC peak areas recognized and calibrated with standard references (corresponding to >98% of the total peaks of the chromatogram). 2 EVs = extracellular vesicles. Values are expressed in percentages relative to the sum of all the quantities of the recognized peaks ± standard error of the mean (S.E.M) from the analyses of n = 8 cell samples of each type; statistical significance is estimated: * p-value ≤ 0.05; ** p-value ≤ 0.003; *** p-value ≤ 0.0006. Details of the statistical analysis are reported in the Materials and Methods Section.
Figure 2Evaluation of desaturase and elongase expression in PC3 cells by qRT-PCR (quantitative real Time polymerase chain reaction). X-axis presents 4 desaturase and 7 elongase enzymes. Y-axis represents the log2 (fold-change) of PC3 with respect to LNCaP cells. Fold-change was calculated by the comparative CT method (ΔΔCT) using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as control for ΔCt and calculating ΔΔCt by subtracting ΔCt for PC3 to ΔCt for LNCaP.